関連する実験動画

Updated: Feb 22, 2026

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models
08:44

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Published on: November 11, 2014

8.5K

タイ・サックス病におけるHEXA遺伝子変異のピリメタミンベースのターゲティング: 計算分析による分析

S Ranjani1, Sidharth Kumar N1, N Madhana Priya1

  • 1Department of Biotechnology, Faculty of Biomedical Sciences & Technology, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, India.

Journal of biomolecular structure & dynamics
|February 20, 2026
PubMed
まとめ

テイ・サックス病 (Tay-Sachs disease,TSD) は,HEXA酵素欠乏によって引き起こされる神経変性疾患である. コンピュータによる分析により,疾患に関連する変異 (W474C,W485R) が特定され,ピリメタミンが確認されました.

キーワード:
HEXA HEXA HEXAは,ヘクサで表記されている.テイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは,タイ・サックス病 (Tay Sachs disease) とは有害で有害である.ドッキング・ドッキングダイナミクスダイナミクスイン-シリコ・ココ・インピリメタミン (Pyrimethamine) とは

さらに関連する動画

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

9.2K
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.9K

関連する概念動画

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
20